Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Brazil / NCT06808386
Enrolling by invitation Not applicable

Effects of Training Frequency on Patellofemoral Pain Rehabilitation.

NCT06808386 · tracked via the Priya Life Science Brazil tracker
Phase
Not applicable
Started
2025-02-24
Last updated
2025-02-05

Condition(s) studied

Anterior Knee Pain

Investigational drug(s) / intervention(s)

Strengthening 2 times per weekStrengthening 3 times per week

Strengthening 2 times per week: This group will consist of participants with patellofemoral pain and will receive treatment twice a week.

Strengthening 3 times per week: This group will consist of participants with patellofemoral pain and will receive treatment thrice a week.

Study summary

This clinical trial aims to determine the optimal frequency of exercise therapy for improving pain, function, and quality of life in participants with patellofemoral pain. The main questions it aims to answer are:

Does exercising twice a week provide the same benefits as exercising three times a week for individuals with patellofemoral pain? What are the optimal dosage, volume, and weekly exercise frequency for treating patellofemoral pain?

The investigators will compare two groups of participants: one group of participants receiving exercise therapy twice a week and another group receiving exercise therapy three times a week. Both groups will follow the same exercise protocol targeting the muscles of the hip and knee joints.

Participants:

84 volunteers (both male and female) with patellofemoral pain Physically active individuals aged between 18 and 40 years

Interventions:

Participants will be randomly assigned to one of two groups Both groups will perform the same exercises for hip and knee muscle strengthening Group A will exercise three times per week Group B will exercise two times per week The intervention will last for six consecutive weeks

Assessments: Participants will be evaluated at the following time points:

Before the intervention After the 4th and 6th week of intervention 6 months and 1 year after the end of the intervention

The primary Outcome Measure will be pain intensity.

Secondary Outcome Measure:

Anterior knee pain during daily activities Kinesiophobia Pain-related self-efficacy Chronic pain-related self-efficacy Catastrophizing Muscle strength 3D Movement analysis

Data Analysis:

The investigators will use an intention-to-treat analysis, which means that all participants will be included in the study, regardless of whether they completed the treatment as planned.

Appropriate statistical tests will be used to compare differences within and between the two groups, considering the time points and group factors.

A 5% significance level will be adopted, which means there is a 5% chance that the results are due to random variation rather than the treatment effect.

Eligibility

Sex
ALL
Min age
18 Years
Max age
40 Years
Healthy volunteers
No
Inclusion Criteria: This study will include physically active individuals of both sexes, aged between 18 and 40 years, who have been experiencing patellofemoral pain and anterior knee pain for at least three months. Participants must have a score of at least three points on the Visual Analog Scale during any of the following activities: running, squatting, sitting for long periods with the knee bent, and climbing or descending stairs. Selection will be based on responses provided in the International Physical Activity Questionnaire. Exclusion Criteria: Exclusion criteria include the following: a history of lower limb or spine surgery, patellar dislocation, anterior knee pain resulting from trauma, coexisting conditions in the knee joint such as meniscal and/or ligament injuries, lateral and/or posterior knee pain, cardiovascular issues or locomotion disorders that could impact the assessment, pregnancy, and a limb length discrepancy greater than 1 cm.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Nove de Julho University São Paulo São Paulo

More University of Nove de Julho trials in Brazil

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06808386 on ClinicalTrials.gov ↗ ← All trials in Brazil